A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.
Osteopontin (OPN) has been implicated as an important mediator of breast cancer progression and metastasis and has been investigated for use as a potential therapeutic target in the treatment of breast cancer. However, the in vivo antitumor effect of anti-OPN antibodies on breast cancer has not been reported. In this study, a mouse anti-human OPN antibody (1A12) was humanized by complementarity-determining region grafting method based on computer-assisted molecular modeling. A humanized version of 1A12, denoted as hu1A12, was shown to possess affinity comparable to that of its parental antibody. The ability of hu1A12 to inhibit cell migration, adhesion, invasion and colony formation was assessed in a highly metastatic human breast cancer cell line MDA-MB-435S. The results indicated that hu1A12 was effective in inhibiting the cell adhesion, migration, invasion and colony formation of MDA-MB-435S cells in vitro. hu1A12 also showed significant efficacy in suppressing primary tumor growth and spontaneous metastasis in a mouse lung metastasis model of human breast cancer. The specific epitope recognized by hu1A12 was identified to be (212)NAPSD(216), adjacent to the calcium binding domain of OPN. Our data strongly support that OPN is a potential target for the antibody-based therapies of breast cancer. The humanized anti-OPN antibody hu1A12 may be a promising therapeutic agent for the treatment of human breast cancer.
Dai
Jianxin
J
International Joint Cancer Institute and General Hospital Cancer Center, The Second Military Medical University, Shanghai, People's Republic of China.
Li
Bohua
B
Shi
Jinping
J
Peng
Ling
L
Zhang
Dapeng
D
Qian
Weizhu
W
Hou
Sheng
S
Zhao
Lei
L
Gao
Jie
J
Cao
Zhiguo
Z
Zhao
Jian
J
Wang
Hao
H
Guo
Yajun
Y
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000196:embryology / Q000473:pathology; D018604:Epitope Mapping; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D053495:Osteopontin / Q000235:genetics / Q000276:immunology*; D011995:Recombination, Genetic; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D053495:Osteopontin
J Biol Chem. 1994 Sep 16;269(37):23280-5
8083234
J Biol Chem. 2003 Aug 1;278(31):28593-606
12771144
Anticancer Res. 1989 Sep-Oct;9(5):1291-9
2686530
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90
14734468
Lancet. 2001 Jul 28;358(9278):277-86
11498214
Int Immunopharmacol. 2007 Nov;7(11):1460-70
17761350
J Cell Mol Med. 2008 Dec;12(6A):2305-18
18266970
Int J Cancer. 1998 Oct 23;79(5):502-8
9761120
Am J Pathol. 1994 Sep;145(3):610-23
8080043
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029-33
2513570
J Biol Chem. 2003 Apr 18;278(16):14487-97
12473670
Int J Oncol. 2004 May;24(5):1235-44
15067347
Cancer Res. 2002 Jun 15;62(12):3417-27
12067984
Int J Exp Pathol. 2000 Dec;81(6):373-90
11298186
Nat Med. 2003 Apr;9(4):416-23
12640447
Lung Cancer. 2007 Sep;57(3):302-10
17482311
Am J Pathol. 2007 Aug;171(2):682-92
17620367
Am J Pathol. 2006 Jul;169(1):233-46
16816376
Clin Cancer Res. 1997 Apr;3(4):605-11
9815727
Ann N Y Acad Sci. 1995 Apr 21;760:299-301
7785904
J Immunol Methods. 1994 Feb 10;168(2):149-65
8308291
Protein Eng. 1991 Oct;4(7):773-83
1798701
Oncogene. 1999 Jul 22;18(29):4237-46
10435636
Lancet. 2005 Dec 17;366(9503):2087-106
16360786
Biochem J. 1994 Oct 1;303 ( Pt 1):255-62
7945249
J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29
12013531
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087-97
17548669
Immunology. 2005 Dec;116(4):487-98
16313362
Cancer Res. 1994 Feb 1;54(3):832-7
8306346
Carcinogenesis. 2005 Apr;26(4):741-51
15661802
J Surg Res. 2004 Oct;121(2):228-41
15501463
J Neurosci. 2007 Mar 28;27(13):3603-11
17392476
FASEB J. 1993 Dec;7(15):1475-82
8262332
Biol Trace Elem Res. 2006 Jan;109(1):55-60
16388103
Crit Rev Oncog. 1996;7(3-4):261-91
9258606
Immunol Today. 1993 Jun;14(6):243-6
8397764
Nature. 1984 Dec 13-19;312(5995):643-6
6095115
Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5
6436822
Arthritis Rheum. 2008 Jul;58(7):2041-52
18576331
Nat Rev Cancer. 2002 Aug;2(8):563-72
12154349
Curr Mol Med. 2001 Nov;1(5):621-32
11899236
Clin Exp Metastasis. 2006;23(2):123-33
16830223
Trends Cell Biol. 2006 Feb;16(2):79-87
16406521
J Immunol. 1996 Apr 15;156(8):2840-50
8609403
Biochim Biophys Acta. 1996 Nov 8;1314(1-2):13-24
8972713
Nature. 1986 May 29-Jun 4;321(6069):522-5
3713831
Cancer Res. 1985 Feb;45(2):879-85
3871353
J Immunol. 1993 Sep 1;151(5):2623-32
8360482
J Cell Biochem. 1994 Feb;54(2):247-55
8175899
Mol Biotechnol. 2004 Jan;26(1):39-60
14734823